BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Domenici E, Muglia P. The search for peripheral disease markers in psychiatry by genomic and proteomic approaches. Expert Opinion on Medical Diagnostics 2007;1:235-51. [DOI: 10.1517/17530059.1.2.235] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Inkster B, Rao AW, Ridler K, Nichols TE, Saemann PG, Auer DP, Holsboer F, Tozzi F, Muglia P, Merlo-pich E, Matthews PM. Structural Brain Changes in Patients with Recurrent Major Depressive Disorder Presenting with Anxiety Symptoms. Journal of Neuroimaging 2011;21:375-82. [DOI: 10.1111/j.1552-6569.2010.00515.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
2 Fryar-Williams S, Strobel JE. Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis. Biomark Res 2015;3:3. [PMID: 25729574 DOI: 10.1186/s40364-015-0028-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
3 Rhee SJ, Han D, Lee Y, Kim H, Lee J, Lee K, Shin H, Kim H, Lee TY, Kim M, Kim SH, Ahn YM, Kwon JS, Ha K. Comparison of serum protein profiles between major depressive disorder and bipolar disorder. BMC Psychiatry 2020;20:145. [PMID: 32245436 DOI: 10.1186/s12888-020-02540-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
4 Domenici E, Willé DR, Tozzi F, Prokopenko I, Miller S, McKeown A, Brittain C, Rujescu D, Giegling I, Turck CW. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One. 2010;5:e9166. [PMID: 20161799 DOI: 10.1371/journal.pone.0009166] [Cited by in Crossref: 226] [Cited by in F6Publishing: 221] [Article Influence: 18.8] [Reference Citation Analysis]
5 Vojdani A. Antibodies as predictors of autoimmune diseases and cancer. Expert Opin Med Diagn 2008;2:593-605. [PMID: 23495772 DOI: 10.1517/17530059.2.6.593] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
6 Comes AL, Papiol S, Mueller T, Geyer PE, Mann M, Schulze TG. Proteomics for blood biomarker exploration of severe mental illness: pitfalls of the past and potential for the future. Transl Psychiatry 2018;8:160. [PMID: 30115926 DOI: 10.1038/s41398-018-0219-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
7 Pedraz M, Araos P, García-Marchena N, Serrano A, Romero-Sanchiz P, Suárez J, Castilla-Ortega E, Mayoral-Cleries F, Ruiz JJ, Pastor A, Barrios V, Chowen JA, Argente J, Torrens M, de la Torre R, Rodríguez De Fonseca F, Pavón FJ. Sex differences in psychiatric comorbidity and plasma biomarkers for cocaine addiction in abstinent cocaine-addicted subjects in outpatient settings. Front Psychiatry 2015;6:17. [PMID: 25762940 DOI: 10.3389/fpsyt.2015.00017] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
8 Pedraz M, Martín-Velasco AI, García-Marchena N, Araos P, Serrano A, Romero-Sanchiz P, Suárez J, Castilla-Ortega E, Barrios V, Campos-Cloute R, Ruiz JJ, Torrens M, Chowen JA, Argente J, de la Torre R, Santín LJ, Villanúa MÁ, Rodríguez de Fonseca F, Pavón FJ. Plasma concentrations of BDNF and IGF-1 in abstinent cocaine users with high prevalence of substance use disorders: relationship to psychiatric comorbidity. PLoS One 2015;10:e0118610. [PMID: 25734326 DOI: 10.1371/journal.pone.0118610] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
9 Li M, Yang X, Sun L, Qing Y, Hu X, Jiang J, Wang D, Cui G, Gao Y, Zhang E, Zhang J, Yang Y, Wan C. Decreased serum apolipoprotein A4 as a potential peripheral biomarker for patients with schizophrenia. J Psychiatr Res 2021;137:14-21. [PMID: 33640722 DOI: 10.1016/j.jpsychires.2021.02.016] [Reference Citation Analysis]
10 Pich EM, Vargas G, Domenici E. Biomarkers for Antipsychotic Therapies. In: Gross G, Geyer MA, editors. Current Antipsychotics. Berlin: Springer Berlin Heidelberg; 2012. pp. 339-60. [DOI: 10.1007/978-3-642-25761-2_13] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
11 Jentsch MC, Van Buel EM, Bosker FJ, Gladkevich AV, Klein HC, Oude Voshaar RC, Ruhé HG, Eisel UL, Schoevers RA. Biomarker approaches in major depressive disorder evaluated in the context of current hypotheses. Biomarkers in Medicine 2015;9:277-97. [DOI: 10.2217/bmm.14.114] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
12 Carboni L, McCarthy DJ, Delafont B, Filosi M, Ivanchenko E, Ratti E, Learned SM, Alexander R, Domenici E. Biomarkers for response in major depression: comparing paroxetine and venlafaxine from two randomised placebo-controlled clinical studies. Transl Psychiatry 2019;9:182. [PMID: 31375659 DOI: 10.1038/s41398-019-0521-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
13 Shin D, Rhee SJ, Lee J, Yeo I, Do M, Joo EJ, Jung HY, Roh S, Lee SH, Kim H, Bang M, Lee KY, Kwon JS, Ha K, Ahn YM, Kim Y. Quantitative Proteomic Approach for Discriminating Major Depressive Disorder and Bipolar Disorder by Multiple Reaction Monitoring-Mass Spectrometry. J Proteome Res 2021;20:3188-203. [PMID: 33960196 DOI: 10.1021/acs.jproteome.1c00058] [Reference Citation Analysis]
14 Carboni L, Delafont B, Ivanchenko E, Ratti E, Learned SM, Alexander R, Domenici E. Folate metabolism biomarkers from two randomised placebo-controlled clinical studies with paroxetine and venlafaxine. World J Biol Psychiatry 2021;22:315-21. [PMID: 32787676 DOI: 10.1080/15622975.2020.1805509] [Reference Citation Analysis]
15 Carboni L, Becchi S, Piubelli C, Mallei A, Giambelli R, Razzoli M, Mathé AA, Popoli M, Domenici E. Early-life stress and antidepressants modulate peripheral biomarkers in a gene–environment rat model of depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2010;34:1037-48. [DOI: 10.1016/j.pnpbp.2010.05.019] [Cited by in Crossref: 65] [Cited by in F6Publishing: 60] [Article Influence: 5.4] [Reference Citation Analysis]
16 Wang Y, Chen J, Chen L, Zheng P, Xu H, Lu J, Zhong J, Lei Y, Zhou C, Ma Q, Li Y, Xie P. Urinary peptidomics identifies potential biomarkers for major depressive disorder. Psychiatry Research 2014;217:25-33. [DOI: 10.1016/j.psychres.2014.02.029] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
17 Preisig M, Waeber G, Vollenweider P, Bovet P, Rothen S, Vandeleur C, Guex P, Middleton L, Waterworth D, Mooser V. The PsyCoLaus study: methodology and characteristics of the sample of a population-based survey on psychiatric disorders and their association with genetic and cardiovascular risk factors. BMC Psychiatry. 2009;9:9. [PMID: 19292899 DOI: 10.1186/1471-244x-9-9] [Cited by in Crossref: 123] [Cited by in F6Publishing: 47] [Article Influence: 9.5] [Reference Citation Analysis]
18 Wollenhaupt-Aguiar B, Librenza-Garcia D, Bristot G, Przybylski L, Stertz L, Kubiachi Burque R, Ceresér KM, Spanemberg L, Caldieraro MA, Frey BN, Fleck MP, Kauer-Sant'Anna M, Passos IC, Kapczinski F. Differential biomarker signatures in unipolar and bipolar depression: A machine learning approach. Aust N Z J Psychiatry 2020;54:393-401. [PMID: 31789053 DOI: 10.1177/0004867419888027] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]